AU2753700A - Use of hydroxyurea and a reverse transcriptase inhibitor to induce autovaccination by autologous hiv - Google Patents

Use of hydroxyurea and a reverse transcriptase inhibitor to induce autovaccination by autologous hiv

Info

Publication number
AU2753700A
AU2753700A AU27537/00A AU2753700A AU2753700A AU 2753700 A AU2753700 A AU 2753700A AU 27537/00 A AU27537/00 A AU 27537/00A AU 2753700 A AU2753700 A AU 2753700A AU 2753700 A AU2753700 A AU 2753700A
Authority
AU
Australia
Prior art keywords
autovaccination
hydroxyurea
induce
reverse transcriptase
transcriptase inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU27537/00A
Inventor
Julianna Lisziewicz
Franco Lori
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/493,769 external-priority patent/US20030095988A1/en
Application filed by Individual filed Critical Individual
Publication of AU2753700A publication Critical patent/AU2753700A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU27537/00A 1999-02-03 2000-02-02 Use of hydroxyurea and a reverse transcriptase inhibitor to induce autovaccination by autologous hiv Abandoned AU2753700A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US24375399A 1999-02-03 1999-02-03
US09243753 1999-02-03
US09493769 2000-01-28
US09/493,769 US20030095988A1 (en) 2000-01-28 2000-01-28 Method of inducing autovaccination against HIV infection using structured treatment interruptions
PCT/US2000/002754 WO2000045844A1 (en) 1999-02-03 2000-02-02 Use of hydroxyurea and a reverse transcriptase inhibitor to induce autovaccination by autologous hiv

Publications (1)

Publication Number Publication Date
AU2753700A true AU2753700A (en) 2000-08-25

Family

ID=26936052

Family Applications (1)

Application Number Title Priority Date Filing Date
AU27537/00A Abandoned AU2753700A (en) 1999-02-03 2000-02-02 Use of hydroxyurea and a reverse transcriptase inhibitor to induce autovaccination by autologous hiv

Country Status (3)

Country Link
EP (1) EP1146904A4 (en)
AU (1) AU2753700A (en)
WO (1) WO2000045844A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030095988A1 (en) * 2000-01-28 2003-05-22 Julianna Lisziewicz Method of inducing autovaccination against HIV infection using structured treatment interruptions
FR2821556B1 (en) * 2001-03-02 2003-04-25 Aventis Pasteur USE OF LIPOPEPTIDES FOR IMMUNOTHERAPY OF HIV + SUBJECTS
EP1355663A1 (en) * 2001-01-26 2003-10-29 The Immune Response Corporation Method for treating an hiv-infected individual by combining immunization with structured interruption of anti-retroviral treatment

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5413999A (en) * 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
WO1994027590A1 (en) * 1993-05-21 1994-12-08 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services New procedure to block the replication of reverse transcriptase dependent viruses by the use of inhibitors of deoxynucleotides synthesis
US5521161A (en) * 1993-12-20 1996-05-28 Compagnie De Developpment Aguettant S.A. Method of treating HIV in humans by administration of ddI and hydroxycarbamide
US6093702A (en) * 1993-12-20 2000-07-25 The United States Of America As Represented By The Department Of Health And Human Services Mixtures of dideoxy-nucleosides and hydroxycarbamide for inhibiting retroviral spread
US6114312A (en) * 1997-03-07 2000-09-05 Research Institute For Genetic And Human Therapy (R.I.G.H.T.) Method of inhibiting human immunodeficiency virus by combined use of hydroxyurea, a nucleoside analog, and a protease inhibitor

Also Published As

Publication number Publication date
EP1146904A4 (en) 2004-09-15
EP1146904A1 (en) 2001-10-24
WO2000045844A1 (en) 2000-08-10

Similar Documents

Publication Publication Date Title
AU6202900A (en) Restoration of a computer to a previous state
AU1694295A (en) Benzoxazinones as inhibitors of hiv reverse transcriptase
SG80631A1 (en) Inhibitors of hiv reverse transcriptase
IL149219A0 (en) Tricyclic compounds useful as hiv reverse transcriptase inhibitors
HK1080852A1 (en) 4-oxoquinoline compounds and utilization thereof as hiv integrase inhibitors
AU2002361868A1 (en) Method of providing a series of disposable absorbent articles to consumers
AU2002253405A1 (en) Adapting a game state to be compatible with a new version of a game
AUPR516901A0 (en) Improvements to a single use syringe
NO953308D0 (en) Inhibitors of HIV reverse transcriptase
AU2002229093A1 (en) Artificial tear composition containing a combination of three demulcents
AU5694901A (en) Methods and compositions for inhibition of membrane fusion-associated events, including hiv transmission
AU2001278955A1 (en) Use of alpha-keratose as a blood plasma expander
AU2753700A (en) Use of hydroxyurea and a reverse transcriptase inhibitor to induce autovaccination by autologous hiv
AU2001270193A1 (en) Pharmaceutical composition containing psyllium fiber and a lipase inhibitor
AU3841393A (en) New quinazolines as inhibitors of HIV reverse transcriptase
AU2002213882A1 (en) Attenuated hiv strains and use thereof
AU2002308503A1 (en) Relationship to other applications and patents
AU2001228327A1 (en) Crystallisation of a glp-1 analogue
AU2001289295A1 (en) Universal input to dc output conversion circuitry
AU2002308774A1 (en) The use of drupes as a soil amendment to control nematodes
AU2001249161A1 (en) Asymmetric synthesis of quinazolin-2-ones useful as hiv reverse transcriptase inhibitors
AU4698399A (en) 1,3-benzodiazepin-2-ones and 1,3-benzoxazepin-2-ones useful as hiv reverse transcriptase inhibitors
AU7666496A (en) Structure based design of inhibitors of hiv-1 reverse transcriptase
AU6463700A (en) Joining of cvd diamond bodies to metal structures
AU2143292A (en) Peptidomimetic inhibitors of hiv gp120 binding to cd4

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase